Sino Biopharmaceutical’s Rovadicitinib Shows Promise in cGVHD Treatment

Sino Biopharmaceutical ( (HK:1177) ) has shared an announcement.

Sino Biopharmaceutical Limited announced the publication of the results from a Phase Ib/IIa clinical study of their innovative drug, Rovadicitinib, in the journal Blood. Rovadicitinib, a first-in-class JAK/ROCK inhibitor, showed promising results in treating chronic graft-versus-host disease (cGVHD) with high response rates and favorable tolerability. The study’s publication highlights the drug’s potential as a new treatment option for cGVHD patients, and the company is advancing its clinical development globally, including applications and trials in China and the United States.

More about Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, focusing on the development of innovative drugs. The company operates in the biopharmaceutical industry, specializing in the creation of treatments for various diseases, with a market focus on hematology and related conditions.

YTD Price Performance: 8.63%

Average Trading Volume: 1,734

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $8.04B

Find detailed analytics on 1177 stock on TipRanks’ Stock Analysis page.